In an interim analysis of an ongoing global trial, semaglutide resolved steatohepatitis in 63% of patients and reduced liver fibrosis, while also promoting weight loss and improving metabolic health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback